Academic Journal
Q1The Lancet Respiratory Medicine
About The Lancet Respiratory Medicine
The Lancet Respiratory Medicine is a scholarly journal published by Elsevier Ltd. SCImago 2025 places it in Q1 with an SJR of 7.652 and an H-index of 212.
Its listed coverage is 2013-2026 and its research categories include Pulmonary and Respiratory Medicine (Q1). The 2025 dataset reports 227 documents and 7704 citations across the latest three-year reporting window.
The Lancet Respiratory Medicine is a highly respected, peer-reviewed medical journal that focuses exclusively on respiratory medicine, critical care, and sleep medicine. Launched in 2013, this journal is part of the prestigious Lancet family, known globally for its high-impact scientific publications. With a strong reputation for publishing groundbreaking clinical research, expert reviews, and insightful commentary, The Lancet Respiratory Medicine plays a vital role in shaping the future of respiratory healthcare.
Leading the Way in Respiratory Research
As one of the top-ranked journals in the field of pulmonary and respiratory health, The Lancet Respiratory Medicine publishes original research articles that have the potential to transform clinical practice. The journal covers a wide range of topics, including asthma, chronic obstructive pulmonary disease (COPD), lung cancer, pulmonary fibrosis, tuberculosis, pneumonia, and acute respiratory distress syndrome (ARDS).
During the COVID-19 pandemic, The Lancet Respiratory Medicine became a go-to source for timely, accurate, and evidence-based information. It published critical studies on ventilation strategies, long COVID, vaccine efficacy in respiratory patients, and the evolving burden on intensive care units.
Trusted by Healthcare Professionals and Researchers Worldwide
Clinicians, researchers, policymakers, and healthcare professionals across the globe rely on The Lancet Respiratory Medicine for its rigorous editorial standards and commitment to scientific integrity. The journal maintains a strict peer-review process, ensuring that each article meets the highest standards of accuracy and relevance.
The journal is indexed in major databases such as PubMed, Scopus, and Web of Science, increasing its visibility and citation potential. With a high impact factor, it is a preferred platform for authors seeking to share novel insights and findings in the respiratory medicine field.
Key Features of The Lancet Respiratory Medicine:
-
High-Quality Research: Publishes original studies, clinical trials, meta-analyses, and systematic reviews.
-
Expert Opinion: Offers commentaries and viewpoints from leading figures in respiratory medicine.
-
Global Reach: Readership includes specialists and institutions in over 100 countries.
-
Multidisciplinary Focus: Covers not only pulmonology but also critical care, sleep medicine, immunology, and infectious disease as related to respiratory health.
A Platform for Innovation and Collaboration
The Lancet Respiratory Medicine also plays a key role in fostering collaboration among clinicians, researchers, and healthcare organizations. It supports continuous medical education through its comprehensive review articles and case studies, helping professionals stay up to date with the latest developments in diagnosis, treatment, and policy-making.
Journal Metrics
Metrics can change by reporting year. Verify time-sensitive values with the publisher or indexing service.
Aims & Scope
The Lancet Respiratory Medicine is a globally renowned, peer-reviewed journal dedicated to advancing research, education, and clinical practice in the field of respiratory medicine. As part of The Lancet family of journals, it stands at the forefront of publishing high-impact studies, systematic reviews, and commentaries that shape the understanding and treatment of respiratory diseases worldwide.
Focus Areas and Coverage
The journal's scope encompasses a wide range of topics within respiratory medicine, with a strong emphasis on both clinical and translational research. Key focus areas include:
-
Chronic Obstructive Pulmonary Disease (COPD)
-
Asthma and Allergy
-
Lung Cancer
-
Interstitial Lung Diseases
-
Pulmonary Hypertension
-
Cystic Fibrosis
-
Sleep-Disordered Breathing
-
Critical Care and Intensive Care Medicine
-
Infectious Diseases such as tuberculosis and pneumonia
-
Global Respiratory Health Challenges, including air pollution and tobacco use
The journal also addresses emerging respiratory threats such as COVID-19 and other novel respiratory pathogens, making it a crucial platform for timely and evidence-based updates.
Commitment to High-Quality Research
The Lancet Respiratory Medicine maintains rigorous editorial standards to ensure that all published content reflects scientific integrity and clinical relevance. The journal features original research articles, meta-analyses, case studies, and expert opinion pieces, often accompanied by insightful editorials that contextualize findings within the broader medical landscape.
Each manuscript undergoes a meticulous peer-review process, attracting contributions from leading researchers, clinicians, and public health experts around the world.
Global Impact and Influence
The journal has a strong international presence and a high impact factor, which reflects its significant influence in shaping clinical guidelines and respiratory health policies. By fostering collaboration across borders, The Lancet Respiratory Medicine contributes to a more unified approach to diagnosing, managing, and preventing respiratory diseases on a global scale.
Its readership includes pulmonologists, intensivists, allergists, thoracic surgeons, epidemiologists, and healthcare policy makers, making it an essential resource for professionals seeking to stay abreast of the latest developments in the field.
Advancing Public Health and Innovation
In addition to traditional research areas, the journal frequently explores innovative therapies, digital health solutions, and interdisciplinary approaches to patient care. It plays a pivotal role in addressing disparities in respiratory health, advocating for equitable access to care, and highlighting the social determinants of health that influence respiratory outcomes.
Recent Research Articles
Latest publications matched automatically by ISSN.
Pulmonary fibrosis in chILD: bridging the gap
Effrosyni D Manali, Nadia Nathan, Lykourgos Kolilekas, Andrew Bush et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00117-7Survival is not the end(point): the second phase of ECPR care
Juergen Grafeneder, Ingrid Magnet, Priscila Robles, Margaret Herridge et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00280-8RSV vaccination and immunisation programmes accelerating worldwide
Tony Kirby
2026-09 · DOI: 10.1016/s2213-2600(26)00223-7The far-reaching effects of wildfire smoke
The Lancet Respiratory Medicine
2026-09 · DOI: 10.1016/s2213-2600(26)00256-0Rheumatoid arthritis-associated interstitial lung disease: between evidence, expertise, and guidelines
Puja Mehta
2026-09 · DOI: 10.1016/s2213-2600(26)00146-3FAK co-inhibition in KRASG12C-mutated non-small-cell lung cancer
Ziming Li, Shun Lu
2026-09 · DOI: 10.1016/s2213-2600(26)00184-0Clinical characteristics and outcomes in the adult cystic fibrosis population in Europe from 2014 to 2024: analysis of the European Cystic Fibrosis Society Patient Registry
Annalisa Orenti, Kris De Boeck, Eitan Kerem, Pierre-Régis Burgel et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00149-9Prevalence and disease trajectories of pulmonary fibrosis of childhood interstitial lung disease: a register-based, multicentre observational study
Matthias Griese, Simone Reu-Hofer, Julia Ley-Zaporozhan, Birgit Kammer et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00052-4Solange Peters—improving the odds for lung cancer survival
Tony Kirby
2026-09 · DOI: 10.1016/s2213-2600(26)00286-9Ifebemtinib plus garsorasib as first-line treatment for KRASG12C-mutated non-small-cell lung cancer in China: a multicentre, single-arm expansion cohort from a phase 1b/2 trial
Zhengbo Song, Xingya Li, Rongbo Lin, Huaqiu Shi et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00142-6Inconsistency in prescribing biologics for severe asthma and CRwNP
Alda Cardesín, Christian Domingo
2026-09 · DOI: 10.1016/s2213-2600(26)00282-1Lung cancer: sharing progress in an equitable way
The Lancet Respiratory Medicine
2026-09 · DOI: 10.1016/s2213-2600(26)00289-4Early-stage non-small-cell lung cancer: emerging treatments and evolving challenges
Jordi Remon, Tina Cascone, Stephanie P L Saw, Nikolaj Frost et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00221-3Beyond efficacy: registries, equity, and outcomes in the ETI era
Jonathan H Rayment, Jennifer L Taylor
2026-09 · DOI: 10.1016/s2213-2600(26)00189-xSugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (SNaPP): an international, randomised, controlled, phase 4 trial
Kate Leslie, Jai N Darvall, Matthew T V Chan, Philip J Peyton et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00158-xFEF25–75% trajectories from age 7 to 53 years, associations with childhood and parental preconception factors, and midlife COPD risk: a prospective cohort study
Jiacheng Liu, Caroline J Lodge, Jennifer L Perret, Don Vicendese et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00163-3COPA syndrome: a monogenic mimic of rheumatoid arthritis-associated ILD that warrants inclusion in future consensus statements
Anna Agrusti, Alberto Tommasini, Serena Pastore, Alessandro Amaddeo et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00220-1Targeted therapies in advanced non-small-cell lung cancer: new biomarkers and treatment strategies
Lizza E L Hendriks, Jessica J Lin, Daniel S W Tan, Fabian Acker et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00253-5Rheumatoid arthritis-associated interstitial lung disease: screening, diagnosis, and treatment—an expert group consensus statement
Joshua J Solomon, Philippe Dieudé, Scott M Matson, Joyce S Lee et al.
2026-09 · DOI: 10.1016/s2213-2600(26)00094-9Sugammadex versus neostigmine and postoperative pulmonary complications: a word of caution
Ana Fernandez-Bustamante, Matthias Eikermann
2026-09 · DOI: 10.1016/s2213-2600(26)00185-2Reviews
Community Reviews
Version History
April 14, 2025 at 4:25 pm
April 14, 2025